Evotec SE Reports Results of Annual General Meeting 2022

• ALL AGENDA ITEMS ADOPTED WITH THE REQUIRED MAJORITY
• CAMILLA MACAPILI LANGUILLE ELECTED AS NEW MEMBER OF THE SUPERVISORY BOARD; KASIM KUTAY RESIGNS FROM SUPERVISORY BOARD
• AUTHORISED CAPITAL 2022 RESOLVED
• REVISED REMUNERATION SYSTEM FOR MANAGEMENT BOARD APPROVED

HAMBURG, GERMANY / ACCESSWIRE / June 22, 2022 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) today announced that its shareholders approved all proposals the Company's Management put to vote at the Company's virtual Annual General Meeting 2022 with the required majority.

In a presentation titled "Reaching the goal with higher speed and confidence", CEO Dr Werner Lanthaler and CFO Enno Spillner presented Evotec SE's current strategic, scientific and technological developments, highlights of the 2021 business year and the commitment to sustainability/ESG. Evotec is committed to increasing the probabilities of success in research and development. With AI & ML enabled platforms that are based on patient data, human disease models, and biomarkers, Evotec intends to identify clinical relevance early and improve patient stratification strategies.

All actions of the Management Board and the Supervisory Board were approved by the Annual General Meeting 2022 for the fiscal year 2021. Furthermore, the shareholders confirmed the appointment of BDO AG Wirtschaftsprüfungsgesellschaft, Hamburg, as auditors for the fiscal year 2022.

The Annual General Meeting also elected a new member of the Supervisory Board: Effective immediately, Camilla Macapili Languille will become a new member of the Supervisory Board of Evotec SE. Camilla Macapili Languille is Canadian citizen and Head of Life Sciences & Healthcare Investments at the Mubadala Investment Company ("MIC") in Abu Dhabi, United Arab Emirates. Since 2013 she held different positions at MIC and previously worked as an analyst and Investment Manager at JPMorgan Securities Inc. (USA), Virgin Management Ltd. (UK) and Daiwa Capital Advisory Partners (France). Moreover, she has more than 20 years of experience in corporate finance and investments in the areas of private equity, public equities and LP investments, with a focus on healthcare.

So handeln Sie das Kursziel

Der Analyst erwartet ein Kursziel von 15,20€, was eine Steigerung von +7,18% zum aktuellen Kurs entspricht. Mit diesen Produkten können Sie die Kurserwartungen des Analysten übertreffen.

 

Morgan Stanley

 

Alle Partner

Übernehmen

Für Ihre Einstellungen haben wir keine weiteren passenden Produkte gefunden.
Bitte verändern Sie Kursziel, Zeitraum oder Emittent.Alternativ können Sie auch unsere Derivate-Suchen verwenden
Knock-Out-Suche | Optionsschein-Suche | Zertifikate-Suche

WerbungDisclaimer